The formation of 15-oxo-5,8,11,13-(Z,Z,Z,E)-eicosatetraenoic acid (15-oxo-ETE) as a product from rabbit lung 15-hydroxyprostaglandin dehydrogenase (PGDH)-mediated oxidation of 15(S)-hydroperoxy-5,8,11,13-(Z,Z,Z,E)-eicosatetraenoic acid was first reported more than 30 years ago. However, the pharmacological significance of 15-oxo-ETE formation has never been established. We have now evaluated 15-lipoxygenase (LO)-1-mediated arachidonic acid (AA) metabolism to 15-oxo-ETE in human monocytes and mouse RAW macrophages that stably express human 15-LO-1 (R15L cells). A targeted lipidomics approach was used to identify and quantify the oxidized lipids that were formed. 15-oxo-ETE was found to be a major AA-derived LO metabolite when AA was given exogenously or released from endogenous esterified lipid stores by calcium ionophore ( 
2008) and LOs (Jian et al., 2009) or nonenzymatically by the action of reactive oxygen species (Porter et al., 1995) .
Bioactive lipid mediators are increasingly being recognized as important endogenous regulators of angiogenesis (Gonzá-lez-Périz and Clà ria, 2007) . One of the major cascades of bioactive lipid mediator production involves the release of AA from membrane phospholipids followed by COX-2-mediated formation of eicosanoids . Eicosanoids produced by COX-2 are thought to promote tumorigenesis by stimulating angiogenesis (Cha et al., 2006) . It is noteworthy that there is an increased level of lipid peroxidation in atherosclerotic lesions as evidenced by the presence of lipid hydroperoxide-derived bifunctional electrophiles such as 4-hydroxy-2-nonenal (as a pyrrole derivative) (Salomon et al., 2000) .
In contrast to 5-LOs, which strongly prefer free AA as substrate (Jian et al., 2009) , mammalian 15-LOs are capable of oxygenating both free and esterified polyunsaturated fatty acids (Kü hn and O'Donnell, 2006) . 15-LO can also oxygenate even more complex lipid-protein assemblies such as biomembranes (Kü hn and Borchert, 2002) and lipoproteins (Brinckmann et al., 1998) . Type 1 human 15-LO (15-LO-1), mainly expressed by reticulocytes, eosinophils, and macrophages, is the enzyme responsible for converting AA to 15(S)-HPETE and a small amount of 12(S)-hydroperoxy-5,8,10,14-(Z,Z,E,Z)-eicosatetraenoic acid (Bryant et al., 1982) . 15-LO-1 is a cytoplasmic enzyme with up-regulated expression in atherosclerotic lesions and localization at sites of macrophage accumulation (Kü hn and Chan, 1997) . Studies of 15-LO-1 in hematopoietic cells have demonstrated that it translocates to the inner plasma membrane and other non-nuclear membranes (e.g., submitochondrial membranes) after stimulation with calcium (Walther et al., 2004) .
Endothelial cells are activated by murine macrophage 12/ 15-LO activity in the presence of low-density lipoprotein (Huo et al., 2004) . Furthermore, it has been suggested that 15-LO-1 plays an important role in angiogenesis and carcinogenesis (Viita et al., 2008) . Both angiogenesis and tumor formation in two xenograft models were inhibited in transgenic mice overexpressing 15-LO-1 in ECs (Harats et al., 2005) . It has been suggested that several possible pro-versus antiangiogenesis functions are mediated by metabolites derived from 15-LO-mediated lipid oxidation (Viita et al., 2008) . These issues make it difficult to assess the precise contribution of the 15-LO pathway to angiogenesis, atherosclerosis, and tumorigenesis. For example, 15-LO has proinflammatory and anti-inflammatory effects in cell cultures and primary cells and opposite effects on atherosclerosis in two different animal species (Wittwer and Hersberger, 2007) . There is also substantial evidence for a proatherosclerotic effect of 15-LO-1, including its direct contribution to low-density lipoprotein oxidation and to the recruitment of monocytes to the vessel wall (Wittwer and Hersberger, 2007) . The explanation to these conflicting observations might reside in the different biological effects of many lipid mediators generated by 15-LO-1 pathway, which have not yet been fully elucidated (Weibel et al., 2009 ). The present study was designed to elucidate the biosynthesis of 15-oxo-ETE through the actions of 15-LO-1 and 15-PGDH and to explore its potential pharmacological role in angiogenesis, an important mediator of tumorigenesis (Folkman, 2007) .
Materials and Methods

Materials. AA (peroxide-free), 15(S)-HETE, 15-oxo-ETE, [ 2 H 8 ]15(S)-HETE, [
2 H 6 ]5-oxo-ETE, and CAY10397 were purchased from Cayman Chemical (Ann Arbor, MI). CDC was obtained from BIOMOL Research Laboratories (Plymouth Meeting, PA). CI; diisopropylethylamine; 2,3,4,5,6-pentafluorobenzyl bromide (PFB) bromide; and fetal bovine serum (FBS) were purchased from SigmaAldrich (St. Louis, MO). Dulbecco's modified Eagle's medium (DMEM), RPMI 1640 medium, medium 199, phosphate-buffered saline (PBS), D-glucose, L-glutamine, heparin, penicillin, streptomycin, and Geneticin (G-418) were supplied by Invitrogen (Carlsbad, CA). EC growth supplement was purchased from Millipore Bioscience Research Reagents (Temecula, CA). Recombinant human interleukin (IL)-4 was obtained from BD Biosciences (San Jose, CA). Highperformance liquid chromatography (LC) grade water, hexane, methanol, and isopropanol were obtained from Thermo Fisher Scientific (Waltham, MA). Gases were supplied by BOC Gases (Lebanon, NJ).
Mass Spectrometry. The quantitative targeted lipidomics profile was obtained on a triple-quadrupole Finnigan TSQ Quantum Ultra AM mass spectrometer (Thermo Fisher Scientific) equipped for electron capture negative atmospheric pressure chemical ionization (ECAPCI) Mesaros et al., 2009) . Operating conditions were as follows: spray voltage, 4.5 kV; vaporizer temperature, 450°C; heated capillary temperature, 350°C; and discharge current, 30 A applied to the corona needle. A postcolumn addition of 0.75 ml/min methanol was used to prevent buildup of carbon in the source. Nitrogen was used as the sheath gas and auxiliary gas, set at 60 and 10 (in arbitrary units), respectively. Collision-induced dissociation was performed using argon as the collision gas at 1.5 mTorr in the second (rf-only) quadrupole and the collision energy was set at 18 eV. An additional d.c. offset voltage was applied to the region of the second multipole ion guide (Q0) at 5 V to impart enough translational kinetic energy to the ions so that solvent adduct ions dissociate to form sample ions. For multiple reaction monitoring (MRM), unit resolution was maintained for both parent and product ions. The following MRM transitions were monitored: 15-HETEs (m/z 319 3 219), [ 2 H 8 ]-15(S)-HETE (m/z 327 3 226), 15-oxo-ETE (m/z 317 3 273), and [ 2 H 6 ]-5-oxo-ETE (m/z 323 3 279). Liquid Chromatography. Normal phase chiral LC-ECAPCI/MS analyses were conducted using a Waters Alliance 2690 high-performance LC system (Waters, Milford, MA). A Chiralpak AD-H column (250 ϫ 4.6-mm inner diameter, 5 m; Daicel Chemical Industries, Ltd., West Chester, PA) was used for gradient 1 with a flow rate of 1.0 ml/min. Solvent A was hexane and solvent B was methanol/ isopropanol (1:1, v/v). Gradient 1 was as follows: 2% B at 0 min, 2% B at 3 min, 3.6% B at 11 min, 8% B at 15 min, 8% B at 27 min, 50% B at 30 min, 50% B at 35 min, 2% B at 37 min, and 2% B at 45 min. Separations were performed at 30°C using a linear gradient. (Zhu et al., 2008) . Cells were cultured in DMEM supplemented with 10% FBS, 4500 mg/l D-glucose, and 0.5 g/l G-418. Before the treatment for lipidomics analysis, the culture media were replaced with serum-free DMEM. HUVECs were a generous gift from Dr. Vladimir Muzykantov (University of Pennsylvania, Philadelphia, PA). HUVECs were cultured in medium 199 supplemented with 10% FBS, 1000 mg/l L-glutamine, 10,000 mg/l heparin, 15,000 mg/l EC growth supplement, 100,000 units/l penicillin, and 100,000 units/l streptomycin. Primary human monocytes were isolated from the peripheral blood of healthy adult donors and purified by the Biomolecular and Cellular Resource Center, Department of Pathology and Laboratory Medicine (University of Pennsylvania) in accordance with human subject protocols approved by the Internal Review Board of the National Institutes of Health (Bethesda, MD). Cells were cultured in RPMI 1640 medium with 10% FBS, 2 mM L-glutamine, 100,000 units/l penicillin, and 100,000 g/l streptomycin for 2 h. Human IL-4 was added to the cell culture media to reach a final concentration of 1000 pM. Cells were cultured for 40 h at 37°C. Before treatment, cell culture media were replaced with serum-free RPMI 1640 media containing 2 mM L-glutamine. Then, 50 M AA or 5 M CI in ethanol was added to the media, and cells were incubated for 40 min at 37°C. The final concentration of ethanol in the culture media was less than 0.1%. Cells and media were then harvested for further analysis. Cell numbers were counted by a hemocytometer.
15-oxo-ETE
AA or CI Treatment of Primary Human Monocytes. Primary human monocytes were cultured as described above. The media were removed and replaced with serum-free RPMI 1640 medium containing 2 mM L-glutamine. AA (final concentration, 50 M) or CI (final concentration, 5 M) was added to the media. Cells were then incubated for 40 min at 37°C. A portion of cell supernatant (3 ml) was transferred into a glass tube and adjusted to pH 3.0 with 2.5 N hydrochloric acid. Lipids were extracted with diethyl ether (2ϫ 4 ml), and the organic layer was then evaporated to dryness under nitrogen. We added 100 l of acetonitrile, 100 l of PFB bromide in acetonitrile [1:19 (v/v) ], and 100 l of di-isopropylethylamine in acetonitrile [1:9 (v/v) ] to the residue, and the solution was heated at 60°C for 60 min. The solution was allowed to cool down, evaporated to dryness under nitrogen at room temperature, dissolved in 100 l of hexane/ethanol [97:3 (v/v)] , and an aliquot of 20 l was used for normal-phase chiral LC-ECAPCI/MRM/MS analysis using gradient 1 as described above.
AA Treatment of R15L and RMock Cells. R15L cells and RMock cells were cultured in DMEM supplemented with 10% FBS, 4500 mg/l D-glucose, and 0.5 g/l G-418. The media were removed and replaced with serum-free DMEM containing peroxide-free AA (final concentration, 10 M). Cells were then incubated for 0 min, 1 min, 5 min, 10 min, 30 min, 40 min, 1 h, 2 h, 3 h, and 24 h at 37°C. After each incubation, a portion of cell supernatant (3 ml) was transferred into a glass tube, and cell numbers were counted by a hemocytometer. Blank media standards (3 ml) were prepared, spiked with the following amounts of authentic lipid standards [15(R,S)-HETEs and 15-oxo-ETE]: 10, 20, 50, 100, 200, 500, and CI Treatment of R15L Cells. R15L cells were cultured as described above. The media were removed and replaced with serumfree DMEM containing CI (final concentration, 5 M). Cells were then incubated for 0, 1, 5, 10, 30, and 40 min and 1, 2, 3, and 24 h at 37°C. Extraction and quantitation of 15(R,S)-HETEs and 15-oxo-ETE from cell culture media (3 ml) were performed as described above.
AA or CI Treatment of R15L Cells with LO inhibitor CDC. R15L cells were cultured as described above. Cells were treated with either 10 M AA for 10 min or with 5 M CI for 40 min with or without the pretreatment with 20 M CDC for 40 min. Extraction and quantitation of 15-oxo-ETE from cell culture media (3 ml) were performed as described above.
15(S)-HETE or AA Treatment of R15L Cells with 15-PGDH Inhibitor CAY10397. R15L cells were cultured as described above until almost confluent. The media were removed and replaced with serum-free DMEM containing various doses of CAY10397 (final concentrations, 0, 5, 10, 15, 25, 50, and 100 M). Cells were then incubated for 4 h at 37°C followed by incubation with additional 15(S)-HETE (final concentration, 50 nM) or AA (final concentration, 10 M) for 10 min. Extraction and quantitation of 15(S)-HETE and 15-oxo-ETE from cell culture media (3 ml) were performed as described above. IC 50 and EC 50 values for CAY10397 were calculated from the equation of the nonlinear regression dose-response curves assuming that the 15(S)-HETE bound to the enzyme following the laws of mass action.
Cell Proliferation 5-Bromo-2-deoxyuridine Assay. Equal numbers (1000 cells/well) of HUVECs were plated as described above in 24-well plates and allowed to attach overnight. Cells were then treated with 15-oxo-ETE dissolved in ethanol (final concentrations, 0, 1, 5, 10, or 20 M). The final concentration of ethanol in the culture media was less than 0.1%. Cell proliferation was assessed for 2 days by a commercially available BrdU assay kit according to the manufacturer's protocol [Roche Cell Proliferation Enzyme-linked immunosorbent assay (ELISA) BrdU (colorimetric); Roche Diagnostics, Indianapolis, IN]. The absorbance at ϭ 370 nm obtained from the assay was normalized to the cell numbers according to a standard curve. Each data point represents the mean value from triplicate wells.
Extraction of Intracellular Eicosanoids in HUVECs after Incubation with 15-oxo-ETE. HUVECs were cultured as described above. The media were removed and replaced with the media containing 1 or 10 M 15-oxo-ETE. Cells were then incubated for 30 min, 1 h, 4 h, 24 h, and 48 h at 37°C. After each incubation, cells were washed with PBS and resuspended in 1 ml of PBS. Blank PBS (1 ml) solutions were prepared, spiked with the following amounts of authentic lipid standards [15(R,S)-HETEs and 15-oxo-ETE]: 10, 20, 50, 100, 200, 500, and 1000 pg. A mixture of internal standards [ 2 H 8 ]15(S)-HETE and [ 2 H 6 ]5-oxo-ETE, 1 ng, each was added to each analytical sample and standard solution. Lipids were extracted with chloroform/methanol [2:1 (v/v); 2ϫ 5 ml]. The organic layer was then washed with 0.9% sodium chloride (2ϫ 1 ml) and evaporated to dryness under nitrogen. Lipid samples were further derivatized with PFB bromide, reconstituted in hexane/ethanol, and analyzed by LC-ECAPCI/MRM/MS as described above. (Fig. 2A) . There was very little 15(R)-HETE (rt, 15.4 min) compared with 15(S)-HETE ( Fig. 2A) . 15-oxo-ETE was also identified (rt, 8.10 min) in IL-4-induced primary human monocytes with either AA or CI treatment (Fig. 2B) . The signal intensity of 15-oxo-ETE was approximately 3-fold lower (1.34 ϫ 10 7 ) than the intensity of 15(S)-HETE (4.35 ϫ 10 7 ) in AA-treated cells and approximately 10-fold lower (5.04 ϫ 10 5 ) than the intensity of 15(S)-HETE (4.05 ϫ 10 6 ) in CI-treated cells (Fig. 2, A  and B 
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at ASPET Journals on May 7, 2017 molpharm.aspetjournals.org negligible amounts of 15(R)-HETE produced in response to AA treatment. Furthermore, 15(S)-HETE level peaked within 5-min treatment of AA (500 pmol/10 6 cells) (Fig. 3B ). In contrast, both 15(R)-and 15(S)-HETE production in RMock cells were close to limit of detection (Fig. 3B) . The time course of 15-oxo-ETE produced in R15L cells upon AA treatment is similar to that of 15(S)-HETE, with maximum level of 15-oxo-ETE observed (120 pmol/10 6 cells) within 5 min of AA treatment and then continuing to diminish over the remainder of the 24-h treatment period (Fig. 3C) . Again, there was very little production of 15-oxo-ETE in RMock cells (Fig. 3C) .
CI-Mediated Production of 15(R,S)-HETEs and 15-oxo-ETE in R15L Cells. CI increases the intracellular calcium concentration, which recruits 15-LO from the cytosol to the inner side of the plasma membrane, oxidizes AA to 15(S)-HPETE, which is subsequently reduced and released as 15(S)-HETE. The chromatograms of LC-ECAPCI/MRM/MS analyses demonstrated the production of the endogenous 15-oxo-ETE (rt, 8.31 min) and 15(S)-HETE (rt, 15.93 min) after 40-min treatment of 5 M CI (Fig. 4A) . Maximum synthesis of 15(S)-HETE was observed at 18 pmol/10 6 cells within 1 h of the CI treatment and decreased to limit of detection after 3 h, whereas there was very little production of 15(R)-HETE (rt, 12.60 min) throughout the time course of the treatment (Fig. 4B) . Likewise, 15-oxo-ETE production peaked at 2 pmol/ 10 6 cells after 40 min of the CI treatment and declined to limit of detection after 3 h (Fig. 4C) .
Effect of CDC on 15-oxo-ETE Production in R15L Cells. CDC is an LO inhibitor that inhibits the production of 15-LO-mediated lipid metabolites (Cho et al., 1991) . R15L cells were treated with 10 M AA for 10 min or with 5 M CI for 40 min, with or without 40-min pretreatment with 20 M CDC. AA treatment alone of R15L cells led to the production of 15-oxo-ETE (40 pmol/10 6 cells) as well as 15(S)-HETE (420 pmol/10 6 cells) (Fig. 5 , A and C, respectively). Pretreatment with CDC resulted in significant inhibition of 15-oxo-ETE production by almost 70% (12 pmol/10 6 cells), and 15(S)-HETE production by almost 95% (20 pmol/10 6 cells) (Fig. 5 , A and C, respectively). CDC treatment by itself did not lead to 15-oxo-ETE or 15(S)-HETE generation (Fig. 5, A and C, respectively). CI treatment generated 2 pmol/10 6 cells of 15-oxo-ETE (Fig. 5B) and 35 pmol/10 6 cells of 15(S)-HETE (Fig.  5D ) in R15L cells. CDC pretreatment abolished both the CI-mediated 15-oxo-ETE and 15(S)-HETE production (Fig. 5,  B and D, respectively) . CDC treatment alone had no effect on 15-oxo-ETE or 15(S)-HETE generation (Fig. 5, B and D,  respectively) . These data further confirmed that both 15(S)-HETE and 15-oxo-ETE were 15-LO-derived metabolites of endogenous AA.
Kinetics of 15(S)-HETE Metabolism to 15-oxo-ETE by R15L Cells. To study the kinetics of 15(S)-HETE metabolism in R15L cells, R15L cells were incubated with 15(S)-HETE (0.9 M) for 3 h. The level of 15(S)-HETE in the cell media declined from 0.9 M to being close to the limit of detection in 3 h (Fig. 6A) . The half-life of 15(S)-HETE was determined to be 21 min, and the pseudo-first-order rate constant (k) was 0.0331 min Ϫ1 (Fig. 6B) . Concomitantly, the level of 15-oxo-ETE in the cell media was observed to peak within 5 min of 15(S)-HETE treatment with the concentration of 0.022 Ϯ 0.002 M and declined to being close to the limit of detection in 3 h (Fig. 6C) . The half-life of 15-oxo-ETE was determined to be 11 min, and the k value was 0.0643 min Ϫ1 (Fig. 6D ). 15-PGDH that oxidizes 15-hydroxyl group of prostaglandins (PGs) to a 15-oxo-group (Berry et al., 1983; Quidville et al., 2006) . To determine the effect of CAY10397 on AA-derived 15(S)-HETE and 15-oxo-ETE, R15L cells were treated with 10 M AA for 10 min, with or without the pretreatment with various doses of CAY10397 (0-100 M) for 4 h. This resulted 
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at ASPET Journals on May 7, 2017 molpharm.aspetjournals.org in a significant inhibition of the production of 15-oxo-ETE (Fig. 7A) and a simultaneous accumulation of 15(S)-HETE in a dose-dependent manner (Fig. 7B) . To confirm that 15-PGDH was the enzyme that oxidized 15(S)-HETE to 15-oxo-ETE, R15L cells were treated with 50 nM 15(S)-HETE for 10 min, with or without the pretreatment with various doses of CAY10397 (0-100 M) for 4 h. 15(S)-HETE treatment alone gave rise to the production of 15-oxo-ETE (3 pmol/10 6 cells). CAY10397 pretreatment resulted in dose-dependent inhibition of 15-oxo-ETE production. The inhibition reached 80% in the presence of 100 M CAY10397 (Fig. 7C) . CAY10397 also caused a concomitant dose-dependent increase in 15(S)-HETE concentrations after the addition of exogenous 15(S)-HETE (Fig. 7D) . CAY10397 treatment by itself in the absence of AA did not lead to 15-oxo-ETE generation (data not shown). The IC 50 of CAY10397 on AA-mediated (Fig. 7A) or 15(S)-HETE-mediated (Fig. 7C) 15-oxo-ETE production were very similar at 17.3 and 13.2 M, respectively. The Hill coefficient for the inhibition of 15(S)-HETE-derived 15-oxo-ETE was Ϫ1.2, indicating that the 15(S)-HETE and CAY10397 were binding at the same site (Fig. 7C ). However, a Hill coefficient of Ϫ2.2 was obtained for the inhibition of AA-derived 15-oxo-ETE, indicating that there was cooperativity in the inhibition of these more complex ligand/binding site interactions (Fig. 7A) . The EC 50 value for CAY10397-induced increase in AA-mediated 15(S)-HETE formation was 19.6 M (Fig. 7B) , which was similar to the IC 50 value of 17.3 M for inhibition of AA-mediated 15-oxo-ETE formation (Fig.  7A) . As expected, the Hill coefficient (Ϫ3.0) deviated from Ϫ1.0 because of cooperativity effects. The effect of CAY10397 on 15(S)-HETE concentrations after the addition of exogenous 15(S)-HETE was too complex to analyze using conventional nonlinear binding models (Fig. 7D) .
Effect of 15-oxo-ETE on Proliferation of HUVECs.
To examine the effect of 15-oxo-ETE on cell proliferation, colorimetric BrdU ELISAs were performed on HUVECs treated with different concentrations (1-20 M) of 15-oxo-ETE for a 48-h period. BrdU incorporation was analyzed, and the corresponding cell number was determined from a standard curve. DNA synthesis in the HUVECs (as measured by BrdU incorporation) was inhibited by 15-oxo-ETE. This resulted in a dose-dependent decrease in cellular proliferation as reflected by the cell count determined from the BrdU standard curve (Fig. 8A) .
15-oxo-ETE Uptake into HUVECs. Cells were incubated with 1 or 10 M 15-oxo-ETE for 48 h. For 1 M 15-oxo-ETE incubation, the intracellular concentrations of 15-oxo-ETE were measured during the time course. The intracellular concentrations of 15-oxo-ETE increased from below the limit of detection at 0 min to 408.08 Ϯ 12.13 nM at 30 min, 154.18 Ϯ 14.91 nM at 1 h, 70.18 Ϯ 9.85 nM at 4 h, and below the limit of detection after 24 h (Fig. 8B) . In HUVECs incubated with 10 M 15-oxo-ETE, the intracellular concentrations of 15-oxo-ETE were measured at 3.19 Ϯ 1.10 M at 30 min, 2.48 Ϯ 0.21 M at 1 h, 2.42 Ϯ 0.52 M at 4 h, and below the limit of detection after 24 h (Fig. 8C) .
Discussion
IL-4-stimulated human monocytes were found to secrete primarily 15(S)-HETE and 15-oxo-ETE when treated with exogenous AA or with CI (Fig. 2) . Brinckmann et al. (1998) reported that 15-LO-1 translocated to plasma membrane in a calcium-dependent manner in rabbit hematopoietic cells and that the translocation activated the oxygenase activity of the enzyme. It is known that 15-LO-1 has a broad substrate Donnell, 2006) . Furthermore, Maskrey et al. (2007) showed that when IL-4-treated monocytes were stimulated with CI, they generated predominantly esterified 15-HETE, with manyfold less free 15-HETE (Maskrey et al., 2007) . These studies suggest that CI treatment of the monocytes resulted in translocation of 15-LO-1 to the plasma membrane so that it was no longer present the cytosol. 15(S)-HPETE was then formed primarily on esterified AA rather than from free of AA released by CI-mediated translocation of cytosolic phospholipase A 2 (cPLA 2 ) to the membrane. The resulting esterified 15(S)-HPETE was then reduced to 15(S)-HETE (Schnurr et al., 1999) and a significant amount then released by cPLA 2 -mediated hydrolysis of the esterified 15(S)-HETE and released from the cells as suggested by Chaitidis et al. (1998) . Indeed, CI treatment of R15L cells led to the production of 15(S)-HETE and 15-oxo-ETE (Fig. 2) , confirming that they are metabolites of endogenously derived AA. These data also suggest that 15(S)-HETE is the predominant precursor of 15-oxo-ETE in 15-LO-1-mediated metabolism of endogenously derived AA. This contrasts with COX-2-mediated formation of 15-oxo-ETE, which could be derived from 15(S)-HPETE, 15(S)-HETE, or the corresponding 15(R)-enantiomers .
A targeted quantitative chiral lipidomics analysis showed that 15(S)-HETE and 15-oxo-ETE were also major metabolites derived from exogenous and endogenous AA in R15L cells (Figs. 3 and 4) . Moreover, the RMock cells that express no human 15-LO-1 failed to generate these metabolites (Figs.  3 and 4) . Pretreatment of R15L cells with CDC, an LO inhibitor, led to a significant reduction in 15-oxo-ETE and 15(S)-HETE levels that were produced by AA treatment alone (Fig. 5, A and C, respectively) . CDC pretreatment also led to complete inhibition of 15-oxo-ETE and 15(S)-HETE production by CI treatment in R15L cells (Fig. 5, B and D, respectively) . CDC treatment by itself generated no 15(S)-HETE and 15-oxo-ETE in R15L cells. Thus, these data provide further evidence that 15(S)-HETE and 15-oxo-ETE are 15-LO-specific metabolites of AA. 15(S)-HETE was found to be rapidly converted into 15-oxo-ETE, with approximately 90% conversion occurring within 3 h in the R15L cells (Fig. 6A) . A kinetic plot (Fig. 6B) revealed that the half-life of 15(S)-HETE in R15L cells was 21 min, with a pseudo first-order rate constant of 0.0331 min Ϫ1 . These data are consistent with findings from a similar study involving COX-2 expressing rat intestinal epithelial cells .
15-PGDH catalyzes NAD ϩ -mediated oxidation of 15(S)-hydroxyl group of PGs and lipoxins (Quidville et al., 2006; Tai et al., 2007) . It is a key PG catabolism enzyme, converting, e.g., PGF 2␣ to 15-oxo-PGF 2␣ (Fig. 1) . Our previous studies had established 15-oxo-ETE as a downstream metabolite of 15(S)-HETE ; however, the enzyme responsible for this oxidation was not identified. In the present study, we have shown that the specific 15-PGDH inhibitor CAY10397 significantly decreased the production of 15-oxo-ETE and the metabolism of 15(S)-HETE in the macrophages treated with either AA (Fig. 7A) or 15(S)-HETE (Fig. 7C) . The IC 50 values for CAY10397-mediated 15-oxo-ETE inhibition were determined to be 17.3 and 13.2 M, respectively. There was a concomitant increase in 15(S)-HETE concentrations after inhibition of AA- (Fig. 7B ) and 15(S)-HETE-mediated (Fig. 7D) 15-oxo-ETE formation. These data clearly show that 15-oxo-ETE arose through the oxidation of 15(S)-HETE by murine 15-PGDH. Mouse 12/15 LO, which is the counterpart of human 15-LO-1, produces both 12-LO-and 15-LO-derived lipid metabolites (Kü hn and O'Donnell, 2006; Middleton et al., 2006) . Thus, it is not clear that the phenotypes in 12/15-LO-deficient mice are due to lack of 12-LO-or 15-LO-derived lipid mediators. In this regard, the mouse R15L macrophage cell line, which expresses human 15-LO-1, 
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at ASPET Journals on May 7, 2017 molpharm.aspetjournals.org provided an excellent model to identify 15-LO-derived lipid metabolites. 15-oxo-ETE was rapidly cleared from the R15L cells, with a half-life of only 11 min, indicating that it underwent further metabolism (Fig. 6D) . We showed previously that 15-oxo-ETE forms a GSH-adduct through GSH S-transferasemediated Michael addition . Other studies have shown that AA-derived metabolites, such as leukotriene C 4 and 5-oxo-ETE, can also form GSH-adducts (Murphy and Zarini, 2002; Blair, 2006) . This suggests that 15-oxo-ETE is also metabolized to a GSH-adduct in the R15L cells, which would account for its rapid clearance.
A previous study reported that 15-oxo-ETE has very low but detectable chemotactic activity in human monocytes in vitro (Sozzani et al., 1996) . Another study reported that 15-oxo-ETE can inhibit proliferation in breast cancer cell lines, but only at concentrations exceeding 100 M (O' Flaherty et al., 2005) . The present study has shown that 15-oxo-ETE inhibits BrdU incorporation and HUVEC proliferation in a time-dependent manner at much lower concentrations (down to 1 M) than reported for breast cancer cells (Fig. 8A) . Rapid 15-oxo-ETE uptake in R15L cells was quantified to confirm that this pharmacological effect was in fact due to the presence of intracellular 15-oxo-ETE. Rapid uptake was observed at extracellular concentrations of 1 M (Fig. 8B ) and 10 M (Fig. 8C) , showing that 15-oxo-ETE can readily cross the plasma membrane.
The 15-oxo-ETE analogs 5-oxo-ETE and 15-deoxy-⌬ 12,14 -prostaglandin J 2 (15d-PGJ 2 ) (Fig. 1 ) modulate cell proliferation and apoptosis as peroxisome proliferator-activated receptor (PPAR) ␥ agonists (O'Flaherty et al., 2005) . PPAR␥ agonists inhibit experimental models of atherosclerosis and the formation of macrophage foam cells (Li et al., 2004) . It has been proposed that 15d-PGJ 2 inhibits proliferation by covalently binding to the thiol residues in inhibitor of nuclear factor-B kinase or p50 subunit of nuclear factor-B through a Michael addition reaction to block the proteins from performing their survival function, using a PPAR␥-independent mechanism (Cernuda-Morollón et al., 2001) . The similar structural features present in 5-oxo-ETE, 15d-PGJ 2 , and 15-oxo-ETE (Fig. 1) suggest that 15-oxo-ETE might also modulate cell proliferation and apoptosis through PPAR␥-dependent and/or PPAR␥-independent mechanism.
Our observation that 15-oxo-ETE can inhibit HUVEC proliferation provides a novel mechanism that could promote endothelial dysfunction (Carmeliet, 2005) . It is interesting to note that 15-PGDH is down-regulated in vivo in colorectal cancer (Backlund et al., 2005) . In view of our new findings, it is intriguing to speculate that down-regulation of 15-PGDH inhibits the production of 15-oxo-ETE and suppresses the antiproliferative effect of 15-oxo-ETE on ECs, thus potentially exacerbating colorectal cancer. Moreover, the capability of 15-oxo-ETE to inhibit EC proliferation suggests that it might be involved in other conditions in which macrophage and/or endothelial cell dysfunction play a role such as in chronic inflammation, atherosclerosis, leukemia, and asthma. Chronic inflammation is known to be involved as a critical component in angiogenesis as well as cancer (Fierro et al., 2002) . Therefore, depending on the location and the local environment in vivo, reduction of EC proliferation and migration in response to 15-oxo-ETE treatment might also be responsible for anti-inflammatory activity. Previous studies have demonstrated that overexpression of 15-LO-1 is associated with an anti-inflammatory response in both rabbit and murine models (Merched et al., 2008) . Furthermore, aspirintriggered 15-LO-1 metabolites of AA (lipoxins) have an antiinflammatory activity through inhibition of EC proliferation (Fierro et al., 2002; Serhan et al., 2008) . Lipoxins have also been shown to promote resolution, a process known to involve active biochemical programs that enables inflamed tissues to return to homeostasis . 15-LO-1 activation during the process of inflammation has also been correlated with switching the metabolism of AA and other -3 polyunsaturated fatty acids to produce proresolving lipid mediators such as resolvins and protectins. Taken together, 15-LO-1 up-regulation can result in the production of antiinflammatory as well as proresolving activities . Localized formation of 15-oxo-ETE production in vivo could be involved in both of these processes.
In summary, our study has provided additional insight into IL-4-induced 15-LO-1 signaling in monocyte/macrophages and potential cell-cell interactions (Fig. 9) . After IL-4 binds to its receptor, 15-LO-1 expression is induced via Janus kinase 1 activation, followed by dimerization and nuclear translocalization of signal transducer and activator of transcription (Stat) 6 (Chatila, 2004) . With elevated intracellular calcium Fig. 9 . Formation and action of 15-LO-1-derived eicosanoids in a monocyte/macrophage cell model. IL-4 binds to its receptor, and activates Janus tyrosine kinase 1 (JAK1), which causes dimerization and nuclear translocalization of transcription 6 (Stat6). The dimerized Stat6 binds to DNA stimulating the production of 15-LO-1. When intracellular calcium concentrations increase, 15-LO-1 is recruited to the inner side of the cell membrane where metabolizes AA to 15(S)-HPETE and 15(S)-HETE, which is released by cPLA 2 from the plasma membrane. 15(S)-HETE is then oxidized to 15-oxo-ETE by intracellular 15-PGDH and 15-oxo-ETE is conjugated to form 15-oxo-ETE-GSH adduct (OEG), which is released and hydrolyzed by ␥-glutamyltranspeptidase (GGTP) to give 15-oxo-ETEcysteinylglycine-adduct (OEC). Released intact 15-oxo-ETE can participate in cell-cell interactions such as with ECs to inhibit proliferation. concentrations, 15-LO-1 is recruited to the inner side of the plasma membrane where it converts esterified AA to 15(S)-HPETE. Esterified 15(S)-HPETE is reduced to 15(S)-HETE and released as the free acid by cPLA 2 . The 15(S)-HETE is then oxidized to 15-oxo-ETE by 15-PGDH, and 15-oxo-ETE is conjugated to form a 15-oxo-ETE-GSH-adduct, which is then hydrolyzed by ␥-glutamyltranspeptidase to a 15-oxo-ETEcysteinylglycine-adduct (Fig. 9) . Released 15-oxo-ETE can inhibit EC proliferation that could further prevent EC growth and that in turn could lead to the inhibition of angiogenesis. In the absence of 15-PGDH (Backlund et al., 2005) , no 15-oxo-ETE would be formed and therefore the antiangiogenesis activity on ECs would be lost. This could then lead to increased tumor growth and metastasis. Therefore, these studies provide a pharmacological basis for the design of new targeted therapeutic strategies to inhibit angiogenesis.
